🍁 civid v1

Status and purpose

• Bill C-286 received first reading on June 16, 2026. It has not yet been enacted.
• Its stated purpose is to improve access to hallucinogenic drug medical treatment, not to circumvent existing approval processes for new drugs.

Controlled Drugs and Substances Act

• The bill would define psilocin, psilocybin and their salts as “narcotics” for purposes of the Narcotic Control Regulations. Its summary says this would allow their use for medical treatment under those regulations.
• It would exclude those substances from the definition of “restricted drug” for purposes of Part J of the Food and Drug Regulations.

Food and Drugs Act

• The bill would add the same exclusion from the Part J “restricted drug” definition.
• It would deem a request for priority review status granted on the day the Department receives it if the request concerns a new drug submission for psilocin, psilocybin, their salts, or a substance with a substantially similar chemical structure. The request must be submitted in accordance with the Department’s priority review policy.

Who is affected

• The changes concern people seeking or providing medical treatment involving psilocin or psilocybin, and those submitting relevant new drugs for review.
• Automatic priority review status is not the same as automatic approval of a new drug.

The provided text specifies no costs or coming-into-force date.